Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management

References

• Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. 2017;124(8):901–905.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr Dis Treat. 2008;4(4):743.
   PubMedGoogle Scholar
• Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson’s disease therapy. Ann Neurol. 2003;53(S3):S3–S15.
   PubMedGoogle Scholar
• Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations.Lancet Neurol. 2015;14(8):855–866.
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Akiyama H, et al. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24(4):574–576.
   PubMed Web of Science ®Google Scholar
• Poewe W, Seppi K, Tanner CM, et al., Parkinson disease. Nat Rev Dis Primers. 2017;3(1):17013.
   PubMed Web of Science ®Google Scholar
• Lee VM-Y, Trojanowski JQ. Mechanisms of Parkinson’s disease linked to pathological α-synuclein: new targets for drug discovery. Neuron. 2006;52(1):33–38.
   PubMed Web of Science ®Google Scholar
• Gosavi N, Lee H-J, Lee JS, et al. Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J Biol Chem. 2002;277(50):48984–48992.
   PubMed Web of Science ®Google Scholar
• Cooper AA, Gitler AD, Cashikar A, et al. α-synuclein blocks ER-golgi traffic and rab1 rescues neuron loss in Parkinson’s models. Science. 2006;313(5785):324–328.
   PubMed Web of Science ®Google Scholar
• Smith WW, Jiang H, Pei Z, et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet. 2005;14(24):3801–3811.
   PubMed Web of Science ®Google Scholar
• Cookson MR. α-Synuclein and neuronal cell death. Mol Neurodegener. 2009;4(1):9.
   PubMedGoogle Scholar
• Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science. 2004;305(5688):1292–1295.
   PubMed Web of Science ®Google Scholar
• Stefanis L, Larsen KE, Rideout HJ, et al. Expression of A53T mutant but not wild-type α-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 2001;21(24):9549–9560.
   PubMed Web of Science ®Google Scholar
• Chiba-Falek O, Nussbaum RL. Effect of allelic variation at the NACP–rep1 repeat upstream of the α-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet. 2001;10(26):3101–3109.
   PubMed Web of Science ®Google Scholar
• Corrado L, De Marchi F, Tunesi S, et al. The length of SNCA Rep1 microsatellite may influence cognitive evolution in Parkinson’s disease. Front Neurol. 2018;9:213.
   PubMed Web of Science ®Google Scholar
• George S, Brundin P. Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregation. J Parkinsons Dis. 2015;5(3):413–424.
   PubMedGoogle Scholar
• Xu L, Pu J. Alpha-synuclein in Parkinson’s disease: from pathogenetic dysfunction to potential clinical application. Parkinson’s Dis. 2016;2016:1–10.
   Web of Science ®Google Scholar
• Karmacharya MB, Hada B, Park SR, et al. Low-intensity ultrasound decreases α-synuclein aggregation via attenuation of mitochondrial reactive oxygen species in MPP (+)-treated PC12 cells. Mol Neurobiol. 2017;54(8):6235–6244.
   PubMed Web of Science ®Google Scholar
• Niu S, Zhang L-K, Zhang L, et al. Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson’s disease model. Theranostics. 2017;7(2):344.
   PubMed Web of Science ®Google Scholar
• Alexander G, Schwartzman R, Nukes T, et al. β2‐adrenergic agonist as adjunct therapy to levodopa in Parkinson’s disease. Neurology. 1994;44(8):1511.
   PubMed Web of Science ®Google Scholar
• Hishida R, Kurahashi K, Narita S, et al. Wearing-off” and β2-adrenoceptor agonist in Parkinson’s disease. Lancet. 1992;339(8797):870. .
   PubMed Web of Science ®Google Scholar
• Uc EY, Lambert CP, Harik SI, et al. Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease. Clin Neuropharmacol. 2003;26(4):207–212.
   PubMed Web of Science ®Google Scholar
• Mittal S, Bjørnevik K, Im DS, et al., β2-adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357(6354):891–898.
   PubMed Web of Science ®Google Scholar
• Choucair-Jaafar N, Beetz N, Gilsbach R, et al. Cardiovascular effects of chronic treatment with a β2-adrenoceptor agonist relieving neuropathic pain in mice. Neuropharmacology. 2011;61(1–2):51–60.
   PubMed Web of Science ®Google Scholar
• Khan AR, Yang X, Fu M, et al. Recent progress of drug nanoformulations targeting to brain. J Control Release. 2018;291:37–64.
   PubMed Web of Science ®Google Scholar
• Loureiro JA, Gomes B, Coelho MA, et al. Immunoliposomes doubly targeted to transferrin receptor and to α-synuclein. Future Sci OA. 2015;1(4):4.
   Web of Science ®Google Scholar
• Stefanis L. α-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(2):a009399.
   PubMed Web of Science ®Google Scholar
• Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345(1):27–32.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. science. 1997;276(5321):2045–2047.
   PubMed Web of Science ®Google Scholar
• Krüger R, Kuhn W, Müller T, et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson’s disease. Nat Genet. 1998;18(2):106.
   PubMed Web of Science ®Google Scholar
• Zarranz JJ, Alegre J, Gómez‐Esteban JC, et al. The new mutation, E46K, of α‐synuclein causes Parkinson and lewy body dementia. Ann Neurol. 2004;55(2):164–173.
   PubMed Web of Science ®Google Scholar
• Appel‐Cresswell S, Vilarino‐Guell C, Encarnacion M, et al. Alpha‐synuclein p. H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013;28(6):811–813.
   PubMed Web of Science ®Google Scholar
• Lesage S, Anheim M, Letournel F, et al. G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome. Ann Neurol. 2013;73(4):459–471.
   PubMed Web of Science ®Google Scholar
• Pasanen P, Myllykangas L, Siitonen M, et al. A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson’s disease-type pathology. Neurobiol Aging. 2014;35(9):2180.e1-2180. e5.
   PubMed Web of Science ®Google Scholar
• Chung CY, Koprich JB, Siddiqi H, et al. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV α-synucleinopathy. J Neurosci. 2009;29(11):3365–3373.
   PubMed Web of Science ®Google Scholar
• Garcia-Reitböck P, Anichtchik O, Bellucci A, et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease. Brain. 2010;133(7):2032–2044.
   PubMedGoogle Scholar
• Nemani VM, Lu W, Berge V, et al. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65(1):66–79.
   PubMed Web of Science ®Google Scholar
• Scott DA, Tabarean I, Tang Y, et al. A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration. J Neurosci. 2010;30(24):8083–8095.
   PubMed Web of Science ®Google Scholar
• Yang Q, She H, Gearing M, et al. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science. 2009;323(5910):124–127.
   PubMed Web of Science ®Google Scholar
• Martin LJ, Pan Y, Price AC, et al. Parkinson’s disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci. 2006;26(1):41–50.
   PubMed Web of Science ®Google Scholar
• Li -W-W, Yang R, Guo J-C, et al. Localization of α-synuclein to mitochondria within midbrain of mice. Neuroreport. 2007;18(15):1543–1546.
   PubMed Web of Science ®Google Scholar
• Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008;283(14):9089–9100.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Nemani VM, Wallender EK, et al. Optical reporters for the conformation of α-synuclein reveal a specific interaction with mitochondria. J Neurosci. 2008;28(47):12305–12317.
   PubMed Web of Science ®Google Scholar
• Liu G, Zhang C, Yin J, et al. α-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci Lett. 2009;454(3):187–192.
   PubMed Web of Science ®Google Scholar
• Loeb V, Yakunin E, Saada A, et al. The transgenic overexpression of α-synuclein and not its related pathology associates with complex I inhibition. J Biol Chem. 2010;285(10):7334–7343.
   PubMed Web of Science ®Google Scholar
• Choubey V, Safiulina D, Vaarmann A, et al. Mutant A53T α-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem. 2011;286(12):10814–10824.
   PubMed Web of Science ®Google Scholar
• Edwards DJ, Sorisio DA, Knopf S. Effects of the β2-adrenoceptor agonist clenbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochem Pharmacol. 1989;38(18):2957–2965.
   PubMed Web of Science ®Google Scholar
• Alexander GM, Schwartzman RJ, Grothusen JR, et al. Effect of plasma levels of large neutral amino acids and degree of parkinsonism on the blood‐to‐brain transport of levodopa in naive and MPTP parkinsonian monkeys. Neurology. 1994;44(8):1491.
   PubMed Web of Science ®Google Scholar
• Magistrelli L, Comi C. Beta2-Adrenoceptor Agonists in Parkinson’s Disease and Other Synucleinopathies. J Neuroimmune Pharmacol. 2020;15(1):74–81.
   Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society‐sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170.
   PubMed Web of Science ®Google Scholar
• Gronich N, Abernethy DR, Auriel E, et al. β2‐adrenoceptor agonists and antagonists and risk of Parkinson’s disease. Mov Disord. 2018;33(9):1465–1471.
   PubMed Web of Science ®Google Scholar
• Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol. 2002;110(6):S322–S328.
   PubMedGoogle Scholar
• Bristow MR. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558–569.
   PubMed Web of Science ®Google Scholar
• Robin ED, McCauley R. Sudden cardiac death in bronchial asthma, inhaled beta-adrenergic agents. Chest. 1992;101(6):1699–1703.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–2321.
   PubMed Web of Science ®Google Scholar
• Au DH, Lemaitre RN, Randall Curtis J, et al. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Respir Crit Care Med. 2000;161(3):827–830.
   PubMed Web of Science ®Google Scholar
• Singh N, Joshi A, Toor AP. et al. Drug delivery: advancements and challenges. In: Nanostructures for Drug Delivery. Volume 2. Ecaterina Andronescu, editor. Amsterdam: Elsevier Inc; 2017; 865–886.
   Google Scholar
• Juillerat-Jeanneret L. Critical analysis of cancer therapy using nanomaterials. In: Nanotechnologies for the Life Sciences Volume 6. Challa S. S. R. Kumar, editor. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2007;199–241.
   Google Scholar
• Wilczewska AZ, Niemirowicz K, Markiewicz KH, et al. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020–1037.
   PubMed Web of Science ®Google Scholar
• Patel T, Zhou J, Piepmeier JM, et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):701–705.
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
   PubMed Web of Science ®Google Scholar
• Sophia GA, Paraskevi K,  Dimitrios GF.Liposomes and drug deliver. In: Pharmaceutical manufacturing handbook production and processes. Gad SC, editor. Hoboken, NJ: Wiley-Interscience; 2008; 443–534. Available from: http://site.ebrary.com/lib/ascc/Doc?id=10226725
   Google Scholar
• Olusanya T, Haj Ahmad R, Ibegbu D, et al. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):4.
   Web of Science ®Google Scholar
• Sunderland CJ, Steiert M, Talmadge JE, et al. Targeted nanoparticles for detecting and treating cancer. Drug Dev Res. 2006;67(1):70–93.
   Web of Science ®Google Scholar
• Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 2012;13(1):105–119.
   PubMed Web of Science ®Google Scholar
• Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev. 2013;33(3):457–516.
   PubMed Web of Science ®Google Scholar
• Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRX. 2005;2(1):99–107.
   PubMedGoogle Scholar
• Yue P-J, He L, Qiu S-W, et al. OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma. Mol Cancer. 2014;13(1):1.
   PubMedGoogle Scholar
• Soni V, Kohli DV, Jain SK. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil. J Drug Target. 2008;13(4):245–250.
   Google Scholar
• Qin Y, Fan W, Chen H, et al. In vitro and in vivo investigation of glucose-mediated brain-targeting liposomes. J Drug Target. 2010;18(7):536–549.
   PubMed Web of Science ®Google Scholar
• Gurturk Z, Tezcaner A, Dalgic AD, et al. Maltodextrin modified liposomes for drug delivery through the blood–brain barrier. MedChemComm. 2017;8(6):1337–1345.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):1.
   PubMedGoogle Scholar
• Geszke-Moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C. 2016;68:982–994.
   PubMed Web of Science ®Google Scholar
• Paliwal R, Paliwal SR, Kenwat R, et al. Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Ther Pat. 2020 Mar;30(3):179–194. PubMed PMID: 32003260.
   PubMed Web of Science ®Google Scholar
• He H, Yao J, Zhang Y, et al. Solid lipid nanoparticles as a drug delivery system to across the blood-brain barrier. Biochem Biophys Res Commun. 2019;519(2):385–390.
   PubMed Web of Science ®Google Scholar
• Cacciatore I, Ciulla M, Fornasari E, et al. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv. 2016;13(8):1121–1131.
   PubMed Web of Science ®Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007 Jul 10;59(6):454–477. PubMed PMID: 17570559.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2):97–109.
   PubMed Web of Science ®Google Scholar
• Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013 Jul;10(7):889–905. PubMed PMID: 23550609.
   PubMed Web of Science ®Google Scholar
• Mulik RS, Mönkkönen J, Juvonen RO, et al. Apoptosis-induced anticancer effect of transferrin-conjugated solid lipid nanoparticles of curcumin. Cancer nanotechnol. 2012;3(1):65.
   PubMedGoogle Scholar
• Dal Magro R, Ornaghi F, Cambianica I, et al. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. J Control Release. 2017;249:103–110.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Lima SAC, et al. Apo E-functionalization of solid lipid nanoparticles enhances brain drug delivery: uptake mechanism and transport pathways. Bioconjug Chem. 2017 Apr 19;28(4):995–1004. PubMed PMID: 28355061.
   PubMed Web of Science ®Google Scholar
• Singh I, Swami R, Pooja D, et al. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting. J Drug Target. 2016;24(3):212–223. PubMed PMID: 26219519.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Reis S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnology. 2016;14(1):27.
   PubMedGoogle Scholar
• Liu Z, Zhao H, Shu L, et al. Preparation and evaluation of Baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB. Drug Dev Ind Pharm. 2015;41(3):353–361.
   PubMed Web of Science ®Google Scholar
• Gandomi N, Varshochian R, Atyabi F, et al. Solid lipid nanoparticles surface modified with anti-Contactin-2 or anti-Neurofascin for brain-targeted delivery of medicines. Pharm Dev Technol. 2017;22(3):426–435.
   PubMed Web of Science ®Google Scholar
• Olbrich C, Gessner A, Kayser O, et al. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target. 2008;10(5):387–396.
   Google Scholar
• Mishra V, Bansal K, Verma A, et al. Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics. 2018;10:4.
   Web of Science ®Google Scholar
• Guo Q, Shen XT, Li YY, et al. Carbon nanotubes-based drug delivery to cancer and brain. J Huazhong Univ Sci Technolog Med Sci. 2017 Oct;37(5):635–641. PubMed PMID: 29058274.
   PubMedGoogle Scholar
• Tan JM, Saifullah B, Kura AU, et al. Incorporation of levodopa into biopolymer coatings based on carboxylated carbon nanotubes for PH-dependent sustained release drug delivery. Nanomaterials (Basel). 2018 May 31;8(6):389. PubMed PMID: 29857532; PubMed Central PMCID: PMCPMC6027427.
   Google Scholar
• Alexander P. Moravsky, Eugene M. Wexler, Raouf O. Loutfy. Growth of carbon nanotubes by Arc discharge and Laser ablation method. In: Carbon nanotubes: science and applications. Meyyappan M, editor. Boca Raton, FL: CRC Press; 2005;65–94.
   Google Scholar
• Bethune D, Kiang CH, De Vries M, et al. Cobalt-catalysed growth of carbon nanotubes with single-atomic-layer walls. Nature. 1993;363(6430):605–607.
   Google Scholar
• Cassell AM, Raymakers JA, Kong J, et al. Large scale CVD synthesis of single-walled carbon nanotubes. The Journal of Physical Chemistry B. 1999;103(31):6484–6492.
   Google Scholar
• Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res. 2008;41(1):60–68.
   PubMed Web of Science ®Google Scholar
• Pardo J, Peng Z, Leblanc RM. Cancer targeting and drug delivery using carbon-based quantum dots and nanotubes. Molecules. 2018 Feb 10;23(2):378. PubMed PMID: 29439409; PubMed Central PMCID: PMCPMC6017112.
   PubMed Web of Science ®Google Scholar
• Wang JT, Al-Jamal KT. Functionalized carbon nanotubes: revolution in brain delivery. Nanomedicine (Lond). 2015;10(17):2639–2642. PubMed PMID: 26328513.
   PubMed Web of Science ®Google Scholar
• Ren J, Shen S, Wang D, et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials. 2012 Apr;33(11):3324–3333. PubMed PMID: 22281423.
   PubMed Web of Science ®Google Scholar
• Guo Q, You H, Yang X, et al. Functional single-walled carbon nanotubes ‘CAR’ for targeting dopamine delivery into the brain of parkinsonian mice. Nanoscale. 2017 Aug 3;9(30):10832–10845. PubMed PMID: 28726961.
   PubMed Web of Science ®Google Scholar
• Wakaskar RR. General overview of lipid–polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes. J Drug Target. 2018;26(4):311–318.
   PubMed Web of Science ®Google Scholar
• Elezaby RS, Gad HA, Metwally AA, et al. Self-assembled amphiphilic core-shell nanocarriers in line with the modern strategies for brain delivery. J Control Release. 2017;261:43–61.
   PubMed Web of Science ®Google Scholar
• Ruan H, Chai Z, Shen Q, et al. A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery. J Control Release. 2018;279:306–315.
   PubMed Web of Science ®Google Scholar
• Croy S, Kwon G. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12(36):4669–4684.
   PubMed Web of Science ®Google Scholar
• Gu PF, Xu H, Sui BW, et al. Polymeric micelles based on poly (ethylene glycol) block poly (racemic amino acids) hybrid polypeptides: conformation-facilitated drug-loading behavior and potential application as effective anticancer drug carriers. Int J Nanomedicine. 2012;7:109.
   PubMed Web of Science ®Google Scholar
• Allen C, Yu Y, Maysinger D, et al. Polycaprolactone-b-poly (ethylene oxide) block copolymer micelles as a novel drug delivery vehicle for neurotrophic agents FK506 and L-685,818. Bioconjug Chem. 1998;9(5):564–572.
   PubMed Web of Science ®Google Scholar
• Nance E, Zhang F, Mishra MK, et al. Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. Biomaterials. 2016;101:96–107.
   PubMed Web of Science ®Google Scholar
• Kuang Y, An S, Guo Y, et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm. 2013;454(1):11–20.
   PubMedGoogle Scholar
• Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design A review. J Saudi Chem Soc. 2014;18(2):85–99.
   Web of Science ®Google Scholar
• Li Y, He H, Jia X, et al. A dual-targeting nanocarrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33(15):3899–3908.
   PubMed Web of Science ®Google Scholar
• Mangraviti A, Gullotti D, Tyler B, et al. Nanobiotechnology-based delivery strategies: new frontiers in brain tumor targeted therapies. J Control Release. 2016;240:443–453.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu C, Pang Z. Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules. 2019;9(12):790.
   PubMed Web of Science ®Google Scholar
• Mignani S, Bryszewska M, Zablocka M, et al. Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches. Prog Polym Sci. 2017;64:23–51.
   Web of Science ®Google Scholar
• Lyu Z, Ding L, Huang A-T, et al. Poly (amidoamine) dendrimers: covalent and supramolecular synthesis. Mater Today Chem. 2019;13:34–48.
   Web of Science ®Google Scholar
• Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today. 2015;20(5):536–547.
   PubMed Web of Science ®Google Scholar
• Sun T, Wu H, Li Y, et al. Targeting transferrin receptor delivery of temozolomide for a potential glioma stem cell-mediated therapy. Oncotarget. 2017;8(43):74451.
   PubMedGoogle Scholar
• Aly AE, Waszczak BL. Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier. Expert Opin Drug Deliv. 2015;12(12):1923–1941.
   PubMed Web of Science ®Google Scholar
• Migliore M, Ortiz R, Dye S, et al. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease. Neuroscience. 2014;274:11–23.
   PubMed Web of Science ®Google Scholar
• Sonvico F, Clementino A, Buttini F, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics. 2018;10(1):34.
   PubMed Web of Science ®Google Scholar
• Mandal A, Bisht R, Pal D, et al. Diagnosis and Drug Delivery to the Brain: novel Strategies. In: Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices. Ashim KM, Kishore C, Abhirup M, editors. Amsterdam: Elsevier Inc; 2017. p. 59–83.
   Google Scholar
• Md S, Haque S, Sahni JK, et al. New non-oral drug delivery systems for Parkinson’s disease treatment. Expert Opin Drug Deliv. 2011;8(3):359–374.
   PubMed Web of Science ®Google Scholar
• Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11(1):1–18.
   PubMed Web of Science ®Google Scholar
• Ying W. The nose may help the brain: intranasal drug delivery for treating neurological diseases. Future Neurology. 2008; 3(1):1–4.
   Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654–1673.
   PubMed Web of Science ®Google Scholar
• Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6(4):268–286.
   PubMed Web of Science ®Google Scholar
• Md S, Haque S, Fazil M, et al. Optimised nanoformulation of bromocriptine for direct nose-to-brain delivery: biodistribution, pharmacokinetic and dopamine estimation by ultra-HPLC/mass spectrometry method. Expert Opin Drug Deliv. 2014;11(6):827–842.
   PubMed Web of Science ®Google Scholar
• Jafarieh O, Md S, Ali M, et al. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev Ind Pharm. 2015;41(10):1674–1681.
   PubMed Web of Science ®Google Scholar
• Sharma S, Lohan S, Murthy R. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm. 2014;40(7):869–878.
   PubMed Web of Science ®Google Scholar
• Mittal D, Md S, Hasan Q, et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv. 2016;23(1):130–139. .
   PubMed Web of Science ®Google Scholar
• Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release. 2011;151(2):131–138.
   PubMed Web of Science ®Google Scholar
• Gambaryan P, Kondrasheva I, Severin E, et al. Increasing the efficiency of parkinson’s disease treatment using a poly (lactic-co-glycolic acid)(PLGA) based L-DOPA delivery system. Exp Neurobiol. 2014;23(3):246–252.
   PubMedGoogle Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, et al. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv. 2013;20(1):47–56.
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Belgamwar VS, Tekade AR, et al. Novel surface modified polymer–lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci. 2013;24(9):2101–2115.
   Web of Science ®Google Scholar
• Mustafa G, Baboota S, Ahuja A, et al. Formulation development of chitosan coated intra nasal ropinirole nanoemulsion for better management option of Parkinson: an in vitro ex vivo evaluation. Curr Nanosci. 2012;8(3):348–360.
   Web of Science ®Google Scholar
• Zhao Y-Z, Li X, Lu C-T, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 2014;10(4):755–764.
   PubMed Web of Science ®Google Scholar
• Zhao Y-Z, Jin -R-R, Yang W, et al. Using gelatin nanoparticle mediated intranasal delivery of neuropeptide substance P to enhance neuro-recovery in hemiparkinsonian rats. PloS One. 2016;11:2.
   Web of Science ®Google Scholar
• Hernando S, Herran E, Figueiro-Silva J, et al. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease. Mol Neurobiol. 2018;55(1):145–155.
   PubMed Web of Science ®Google Scholar